Skip to main content

Branded

  • FDA approves single-pill HIV drug

    FOSTER CITY, Calif. — The Food and Drug Administration has approved a new single-pill treatment for HIV made by Gilead Sciences and Johnson & Johnson, Gilead said.

    Gilead announced the approval of Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate). The drug combines Gilead's Truvada with J&J's Edurant.

  • Pfizer to discover, develop drugs with UC San Diego Health Sciences

    NEW YORK — Pfizer will invest up to $50 million over the next five years in drug discovery and development under a collaboration with the University of California San Diego Health Sciences, the drug maker said.

  • FDA sets review date for Bydureon

    SAN DIEGO — The Food and Drug Administration has acknowledged the resubmission of an investigational Type 2 diabetes drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes.

  • Avanir sues Par, Actavis over generic versions of neurological drug

    ALISO VIEJO, Calif. — Drug maker Avanir Pharmaceuticals has filed suit against two generic drug makers seeking to launch versions of a drug used to treat pseudobulbar affect, which causes sudden, involuntary episodes of laughing and crying, and occurs secondary to numerous other neurological conditions.

    Avanir filed the suit in the U.S. District Court for the District of Delaware against Par and Actavis, which had filed for regulatory approval of Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).

  • Endo sales, profits climb in Q2

    CHADDS FORD, Pa. — Profits for Endo Pharmaceutical Holdings rose to $54.6 million during second quarter 2011, up 6% from $51.5 million in second quarter 2010, the drug maker said.

    Sales for the quarter were $607.5 million, compared with $396.5 million in second quarter 2010. Sales of branded drugs were $398.3 million, an 8% increase over last year, which the company attributed to better sales of the pain drug Opana ER and the joint pain drug Voltaren Gel.

  • Pelletier named board chairman at Together Rx Access

    ALEXANDRIA, Va. — Prescription savings program Together Rx Access announced that it has appointed a Pfizer executive to serve as its board of managers chairman.

  • FDA accepts Teva approval application for BDP Nasal HFA

    JERUSALEM — The Food and Drug Administration has accepted an approval application for a drug made by Teva Pharmaceutical Industries for treating allergies, Teva said.

    The Israeli drug maker said the FDA accepted its application for BDP Nasal HFA (beclomethasone dipropionate hydrofluoroalkane) for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis. The drug is a nasal aerosol corticosteroid.

  • Roche drug improves lung function in patients with uncontrolled asthma, study finds

    BASEL, Switzerland — An investigational treatment made by Roche for asthma increased lung function in patients who could not adequately control their disease with inhaled corticosteroids, according to results of a mid-stage clinical trial.

X
This ad will auto-close in 10 seconds